Literature DB >> 26827133

[Update Chagas disease].

Israel Molina1, Fernando Salvador2, Adrián Sánchez-Montalvá2.   

Abstract

The constant migration flows have favored the presence of people with Chagas disease in regions traditionally regarded as non-endemic, such as North America, Europe, Asia and Oceania. This has forced both health authorities and professionals to be updated in order to respond to such a demand for assistance. Recent years have led to significant progress in the field of diagnosis and treatment of Chagas disease, one of the most neglected tropical diseases. Recent clinical trials are providing new evidence that makes the management of these patients, a constant challenge for the professionals involved. Innovative diagnostic tools and therapeutic regimens, allow us to face the future of Chagas disease with optimism.
Copyright © 2016 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Chagas disease; Diagnosis; Diagnóstico; Enfermedad de Chagas; Tratamiento; Treatment; Trypanosoma cruzi

Mesh：

Year:  2016        PMID： 26827133     DOI： 10.1016/j.eimc.2015.12.008

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN： 0213-005X            Impact factor:   1.731


  7 in total

1.  Serum IL-10 Levels and Its Relationship with Parasitemia in Chronic Chagas Disease Patients.

Authors:  Fernando Salvador; Adrián Sánchez-Montalvá; Mónica Martínez-Gallo; Elena Sulleiro; Clara Franco-Jarava; Augusto Sao Avilés; Pau Bosch-Nicolau; Zaira Moure; Aroa Silgado; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

2.  Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity.

Authors:  C F Araujo-Lima; R B Peres; P B Silva; M M Batista; C A F Aiub; I Felzenszwalb; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.

Authors:  F H Guedes-da-Silva; D G J Batista; C F Da Silva; J S De Araújo; B P Pavão; M R Simões-Silva; M M Batista; K C Demarque; O C Moreira; C Britto; G I Lepesheva; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Arthrospira maxima Paradoxical Effect on Trypanosoma cruzi Infection.

Authors:  Oscar A Reboreda-Hernandez; Adriana L Juarez-Serrano; Ivan Garcia-Luna; Nora L Rivero-Ramirez; Rocio Ortiz-Butron; Benjamín Nogueda-Torres; Nayeli Gonzalez-Rodriguez
Journal:  Iran J Parasitol       Date:  2020 Apr-Jun       Impact factor: 1.012

5.  Foodborne Parasitic Diseases in the Neotropics - A Review.

Authors:  F Chávez-Ruvalcaba; M I Chávez-Ruvalcaba; K Moran Santibañez; J L Muñoz-Carrillo; A León Coria; R Reyna Martínez
Journal:  Helminthologia       Date:  2021-06-08       Impact factor: 1.184

6.  Trypanosoma cruzi infection in puerperal women and their neonates at Barcelona, Anzoategui State, Venezuela

Authors:  Norielis Del Carmen Zabala; Mariolga Berrizbeitia; Alicia Jorquera; Jessicca Rodríguez; Leomery Romero
Journal:  Biomedica       Date:  2019-12-01       Impact factor: 0.935

7.  Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.

Authors:  D Molina-Morant; M L Fernández; P Bosch-Nicolau; E Sulleiro; M Bangher; F Salvador; A Sanchez-Montalva; A L P Ribeiro; A M B de Paula; S Eloi; R Correa-Oliveira; J C Villar; S Sosa-Estani; I Molina
Journal:  Trials       Date:  2020-04-15       Impact factor: 2.279
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.